A Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
A Multicenter, Randomized, Double-Blind, Parallel-Controlled Phase I Clinical Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Phesgo® Biosimilar HLX319 vs. EU-Phesgo® in the Neoadjuvant Therapy of HER2-Positive Early or Locally Advanced Breast Cancer
Studieoversigt
Status
Status
Betingelser
Betingelser
Intervention / Behandling
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Undersøgelsestype
Tilmelding (Anslået)
Tilmelding
Fase
Fase
- Fase 1
Kontakter og lokationer
Studiekontakt
Studiekontakt
- Navn: Qi Jin
- Telefonnummer: 86 159 5516 0489
- E-mail: Qi_jin@henlius.com
Deltagelseskriterier
Berettigelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
- Voksen
- Ældre voksen
Tager imod sunde frivillige
Beskrivelse
Inclusion Criteria:
- Voluntary participation in the clinical study and signed the Informed Consent Form (ICF).
- Male or female aged ≥ 18 years old at the time of signing the ICF;
- Histologically confirmed invasive breast cancer, stage II-IIIC, Human Epidermal Growth Factor Receptor 2 (HER2) positive confirmed by central laboratory.
- Participants agree to undergo surgery while meeting the criteria for surgery after neoadjuvant therapy.
- Left ventricular ejection fraction (LVEF) at baseline ≥ 55%.
- An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0-1.
- Adequate major organ functions.
- Women with child-bearing potential have a negative result of serum pregnancy test at screening period (within 7 days prior to the first dose) or if they are infertile, non- lactating, reproduction-age men and women following highly effective contraceptive measures until 7 months after last dose.
Exclusion Criteria:
- Stage IV breast cancer, bilateral breast cancer, or multicentric breast cancer.
- History of other malignancy within 5 years.
- Prior systemic therapy for breast cancer treatment or radiotherapy.
- Patients with a history of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) who have received systemic therapy or radiotherapy to the ipsilateral breast.
- Patients who have undergone excision biopsy of the primary tumor and/or axillary lymph nodes or lymph node dissection.
- Have severe heart disease or medical conditions.
- Participants with viral hepatitis or those with autoimmune hepatitis, sclerosing cholangitis, or liver cirrhosis.
- Human Immunodeficiency Virus (HIV) infection, HIV antibody positive.
- Daily use of corticosteroid treatment is required.
- Sensitivity to any study medications or any of its ingredients or excipients.
- Participants who underwent any major surgery within 28 days prior to the first dose. Or participants who have received local radiotherapy, radiofrequency ablation, or interventional therapy within 2 weeks prior to the first dose.
- Received another interventional clinical trial therapy within 4 weeks prior to enrollment in the study, or intentionally participated in another interventional clinical trial during the entire study period.
- Severe, uncontrolled systemic diseases that may currently interfere with the therapeutic plan.
- Any other conditions which are inappropriate for the study in the opinion of the investigator.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Dobbelt
Antal våben
Våben og indgreb
Deltagergruppe / ArmDeltagergruppe / Arm |
Intervention / BehandlingIntervention / Behandling |
|---|---|
|
Eksperimentel: HLX319
The regimen in the experimental group is HLX319 in combination with docetaxel and carboplatin.
|
HLX319 is a biosimilar of pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
|
Aktiv komparator: EU-Phesgo®
The regimen in the control group is EU-Phesgo® in combination with docetaxel and carboplatin.
|
EU-Phesgo® is an original marketed drug product, with the generic name pertuzumab-trastuzumab monoclonal antibody injection (subcutaneous injection)
|
Hvad måler undersøgelsen?
Primære resultatmål
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Peak concentration (Cmax)
Tidsramme: up to 180 days
|
Peak concentration after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from 0 to 21 days (AUC0-21d)
Tidsramme: up to 180 days
|
Area under the serum drug concentration-time curve from 0 to 21 days after a single drug administration in Cycle 1.
|
up to 180 days
|
|
Steady-state peak concentration (Cmax,ss)
Tidsramme: up to 180 days
|
The steady-state peak concentration after multiple doses administration in Cycle 4.
|
up to 180 days
|
|
Steady-state area under the serum drug concentration-time curve within a dosing interval (AUCss)
Tidsramme: up to 180 days
|
Steady-state area under the serum drug concentration-time curve within a dosing interval after multiple doses administration in Cycle 4.
|
up to 180 days
|
Sekundære resultatmål
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Trough concentration (Ctrough)
Tidsramme: up to 180 days
|
Trough concentration after a single dose administration
|
up to 180 days
|
|
Area under the serum drug concentration-time curve from time 0 to infinity (AUC0-inf)
Tidsramme: up to 180 days
|
Area under the serum drug concentration-time curve from time 0 to infinity after a single dose administration
|
up to 180 days
|
|
Percentage of extrapolated area in the total AUC (%AUCex)
Tidsramme: up to 180 days
|
Percentage of extrapolated area in the total AUC after a single dose administration
|
up to 180 days
|
|
Time to peak concentration (Tmax)
Tidsramme: up to 180 days
|
time to peak concentration after a single dose administration
|
up to 180 days
|
|
Elimination half-life (T1/2)
Tidsramme: up to 180 days
|
elimination half-life after a single dose administration
|
up to 180 days
|
|
Total clearance (CL/F)
Tidsramme: up to 180 days
|
total clearance after a single dose administration
|
up to 180 days
|
|
Terminal phase distribution volume (Vz/F)
Tidsramme: up to 180 days
|
terminal phase distribution volume after a single dose administration
|
up to 180 days
|
|
Mean residence time (MRT)
Tidsramme: up to 180 days
|
mean residence time after a single dose administration
|
up to 180 days
|
|
Steady-state trough concentration (Ctrough,ss)
Tidsramme: up to 180 days
|
steady-state trough concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Average steady-state concentration (Caverage,ss)
Tidsramme: up to 180 days
|
average steady-state concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state time to peak concentration (Tmax,ss)
Tidsramme: up to 180 days
|
steady-state time to peak concentration after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Elimination half-life (T1/2,ss)
Tidsramme: up to 180 days
|
elimination half-life after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state volume of distribution (Vss/F)
Tidsramme: up to 180 days
|
steady-state volume of distribution after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Steady-state total clearance (CLss/F)
Tidsramme: up to 180 days
|
steady-state total clearance after multiple doses administration in Cycle 4
|
up to 180 days
|
|
accumulation ratio based on Cmax (RCmax)
Tidsramme: up to 180 days
|
accumulation ratio based on Cmax after multiple doses administration in Cycle 4
|
up to 180 days
|
|
Accumulation ratio based on AUC (RAUC)
Tidsramme: up to 180 days
|
accumulation ratio based on AUC after multiple doses administration in Cycle 4
|
up to 180 days
|
|
The total pathological complete response (tpCR) rate assessed by the investigator
Tidsramme: up to 180 days
|
up to 180 days
|
|
|
Breast pathologic complete response (bpCR) rate assessed by the investigator
Tidsramme: up to 180 days
|
up to 180 days
|
|
|
Objective response rate (ORR) assessed by the investigator
Tidsramme: up to 180 days
|
according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria
|
up to 180 days
|
|
Incidence and severity of adverse events (AEs)
Tidsramme: up to 180 days
|
severity determined according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version 6.0
|
up to 180 days
|
|
Number of participants with abnormal vital signs
Tidsramme: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal physical examination findings
Tidsramme: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal Laboratory tests results
Tidsramme: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Number of participants with abnormal 12-lead ECG readings
Tidsramme: up to 180 days
|
Detailed Outcome Measure will be defined in the Statistical Analysis Plan
|
up to 180 days
|
|
Positivity rates of anti-drug antibodies (ADA)
Tidsramme: up to 180 days
|
up to 180 days
|
|
|
Positivity rates of neutralizing antibodies (NAb)
Tidsramme: up to 180 days
|
up to 180 days
|
Samarbejdspartnere og efterforskere
Sponsor
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Studiestart
Primær færdiggørelse (Anslået)
Primær færdiggørelse
Studieafslutning (Anslået)
Studieafslutning
Datoer for studieregistrering
Først indsendt
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Først opslået
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering sendt
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
Andre undersøgelses-id-numre
- HLX319-BC001
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .